For decades, Alzheimer’s drug development has focused on removing amyloid plaques. Now the field may be entering a new chapter. Biogen’s experimental therapy, diranersen, is the first drug to show that reducing the tau protein may slow cognitive decline in people with early Alzheimer’s disease. While the Phase 2 results were mixed and larger trials are still needed, researchers see this as an important proof of concept that Alzheimer’s may be treatable through multiple biological pathways, not just amyloid. If future studies confirm these findings, targeting tau could become a major addition to the fight against one of the world’s most devastating diseases. Science rarely moves in a straight line. Progress often comes one breakthrough at a time. #Dementia #Alzheimers #MentalHealth #MarcoSift